{"id":5864,"date":"2022-09-30T01:13:10","date_gmt":"2022-09-30T01:13:10","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=5864"},"modified":"2023-08-29T17:55:44","modified_gmt":"2023-08-29T17:55:44","slug":"invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=5864","title":{"rendered":"Invex Therapeutics \u5728\u83b7\u5f97\u7b2c\u4e8c\u6b21\u6fb3\u5927\u5229\u4e9a\u4f26\u7406\u6279\u51c6\u540e\u5f00\u8f9f\u4e86\u66f4\u591a\u8bd5\u9a8c\u573a\u6240"},"content":{"rendered":"<p>Invex Therapeutics (ASX: IXC) \u5df2\u5728\u6fb3\u5927\u5229\u4e9a\u83b7\u5f97\u7b2c\u4e8c\u4e2aHuman Research Ethics Committee (HREC) \u6279\u51c6\uff0c\u5f00\u59cb\u5176 III \u671f\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u4e3b\u8981\u836f\u7269 Presendin \u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002<\/p>\n<p>HREC\u6279\u51c6\u7684\u7b2c\u4e8c\u4e2a\u9879\u76ee\u5305\u62ec\u53e6\u5916\u4e09\u5bb6\u516c\u7acb\u533b\u9662: \u58a8\u5c14\u672c\u548cLiverpool \u7684Alfred Hospital\u548c\u6089\u5c3c\u7684Sydney Eye\u3002<\/p>\n<p>\u4e00\u65e6\u83b7\u5f97\u673a\u6784\u6388\u6743\uff0c\u533b\u9662\u5c06\u5f00\u59cb\u62db\u52df\u60a3\u8005\u8fdb\u884c III \u671f\u8bd5\u9a8c\uff0c\u8be5\u8bd5\u9a8c\u5df2\u88ab\u6807\u8bb0\u4e3a IIH EVOVE\u3002<\/p>\n<p>Invex \u9996\u5e2d\u79d1\u5b66\u5b98\u517c\u6267\u884c\u8463\u4e8b Alex Sinclair \u6559\u6388\u8868\u793a\uff0c\u8be5\u516c\u53f8\u73b0\u5728\u62e5\u200b\u200b\u6709\u8db3\u591f\u7684\u6fb3\u5927\u5229\u4e9a\u8bd5\u9a8c\u573a\u5730\uff0c\u83b7\u5f97\u4e86\u79c1\u7acb\u548c\u516c\u7acb\u533b\u9662 HREC \u7684\u6279\u51c6\uff0c\u4ee5\u53ca\u6fb3\u5927\u5229\u4e9a\u6cbb\u7597\u7528\u54c1\u7ba1\u7406\u5c40\u7684\u6279\u51c6\u3002<\/p>\n<p>\u5728\u6fb3\u5927\u5229\u4e9a\u9886\u5bfc\u8fd9\u9879\u8bd5\u9a8c\u7684\u662fSydney Eye\u533b\u9662\u3001Liverpool\u533b\u9662\u548cMacquarie \u533b\u9662\u7684\u795e\u7ecf\u773c\u79d1\u987e\u95ee Clare Fraser \u526f\u6559\u6388\u3002<\/p>\n<p>Fraser\u535a\u58eb\u8bf4\uff0c\u8be5\u8bd5\u9a8c\u5c06\u63d0\u4f9b\u5fc5\u8981\u7684\u4e34\u5e8a\u8bc1\u636e\uff0c\u4ee5\u6f5c\u5728\u5730\u652f\u6301\u9488\u5bf9 IIH \u4e13\u5229\u7684\u65b0\u836f\u7269\u7597\u6cd5\uff0c\u5728\u73b0\u6709\u7597\u6cd5\u7f3a\u4e4f\u4e14\u4e34\u5e8a\u9700\u6c42\u5de8\u5927\u7684\u60c5\u51b5\u4e0b\u3002<\/p>\n<p>Sinclair\u6559\u6388\u6307\u51fa\uff0cFraser\u535a\u58eb\u662f\u4e00\u4f4d\u201c\u56fd\u9645\u5730\u4f4d\u5f88\u9ad8\u201d\u7684\u795e\u7ecf\u773c\u79d1\u533b\u751f\u3002<\/p>\n<p>\u9664\u4e86\u4e3aSydney Eye\u533b\u9662\u3001Liverpool\u533b\u9662\u548cMacquarie\u533b\u9662\u63d0\u4f9b\u54a8\u8be2\u5916\uff0cFraser\u535a\u58eb\u8fd8\u4e3a Save the Site Institute \u63d0\u4f9b\u54a8\u8be2\u670d\u52a1\uff0c\u62c5\u4efbNeuro-Ophthalmology Virtual Education Library\u526f\u4e3b\u5e2d\uff0c\u795e\u7ecf\u773c\u79d1\u5b66\u865a\u62df\u6559\u80b2\u56fe\u4e66\u9986\u59d4\u5458\u4f1a\u6210\u5458\uff0c\u5e76\u4e14\u662f\u51e0\u5bb6\u9ad8\u5f71\u54cd\u529b\u773c\u79d1\u671f\u520a\u7684\u7f16\u59d4\u3002<\/p>\n<h2>IIH EVOLVE \u8bd5\u9a8c<\/h2>\n<p>IIH EVOLVE \u8bd5\u9a8c\u5c06\u62db\u52df 240 \u540d\u65b0\u8bca\u65ad\u7684 IIH \u60a3\u8005\uff0c\u4ee5\u786e\u5b9a Presendin \u4e0e\u5b89\u6170\u5242\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002<\/p>\n<p>Presendin \u5c06\u5728 24 \u5468\u5185\u6bcf\u5468\u7ed9\u836f\u4e00\u6b21\uff0c\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\u662f\u89c2\u5bdf\u9885\u5185\u538b\u76f8\u5bf9\u4e8e\u539f\u59cb\u57fa\u7ebf\u7684\u53d8\u5316\u3002<\/p>\n<p>\u6b21\u8981\u7ec8\u70b9\u5c06\u662f\u63ed\u793a\u89c6\u529b\u548c\u5934\u75db\u75c7\u72b6\u7684\u6539\u5584\u3002<\/p>\n<p>\u8be5\u8bd5\u9a8c\u5c06\u5728\u5168\u7403 40 \u4e2a\u4e34\u5e8a\u7ad9\u70b9\u8fdb\u884c\u3002<\/p>\n<p>Invex \u7684\u4e3b\u8981\u5019\u9009\u836f\u7269 Presendin \u662f\u5df2\u7ecf\u6279\u51c6\u7684\u836f\u7269\u827e\u585e\u90a3\u80bd\u7684\u6539\u7248\u7248\u672c\uff0c\u827e\u585e\u90a3\u80bd\u4e4b\u524d\u66fe\u4e0a\u5e02\u7528\u4e8e\u6cbb\u7597 2 \u578b\u7cd6\u5c3f\u75c5\u3002<\/p>\n<p>IIH \u60a3\u8005\u7684\u9885\u5185\u538b\u201c\u4e25\u91cd\u5347\u9ad8\u201d\uff0c\u8fd9\u4f1a\u5bfc\u81f4\u4f7f\u4eba\u8870\u5f31\u7684\u5934\u75db\u5e76\u4f1a\u538b\u8feb\u89c6\u795e\u7ecf\u3002<\/p>\n<p>\u8fd9\u79cd\u60c5\u51b5\u6700\u5e38\u89c1\u4e8e\u80a5\u80d6\u7684\u5973\u6027\uff0c\u53d1\u75c5\u5e74\u9f84\u901a\u5e38\u5728 20-30 \u5c81\u4e4b\u95f4\u3002<\/p>\n<p>\u636e Invex \u79f0\uff0cIIH \u5728\u6b27\u76df\u3001\u82f1\u56fd\u548c\u7f8e\u56fd\u7684\u6f5c\u5728\u5e02\u573a\u7ea6\u4e3a 16 \u4ebf\u6fb3\u5143\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Invex Therapeutics (ASX: IXC) \u5df2\u5728\u6fb3\u5927\u5229\u4e9a\u83b7\u5f97\u7b2c\u4e8c\u4e2aHuman Research Ethics Committee (HREC) \u6279\u51c6\uff0c\u5f00\u59cb\u5176 III \u671f\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u4e3b\u8981\u836f\u7269 Presendin \u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002 HREC\u6279\u51c6\u7684\u7b2c\u4e8c\u4e2a\u9879\u76ee\u5305\u62ec\u53e6\u5916\u4e09\u5bb6\u516c\u7acb\u533b\u9662: \u58a8\u5c14\u672c\u548cLiverpool \u7684Alfred Hospital\u548c\u6089\u5c3c\u7684Sydney Eye\u3002 \u4e00\u65e6\u83b7\u5f97\u673a\u6784\u6388\u6743\uff0c\u533b\u9662\u5c06\u5f00\u59cb\u62db\u52df\u60a3\u8005\u8fdb\u884c III \u671f\u8bd5\u9a8c\uff0c\u8be5\u8bd5\u9a8c\u5df2\u88ab\u6807\u8bb0\u4e3a IIH EVOVE\u3002 Invex \u9996\u5e2d\u79d1\u5b66\u5b98\u517c\u6267\u884c\u8463\u4e8b Alex Sinclair \u6559\u6388\u8868\u793a\uff0c\u8be5\u516c\u53f8\u73b0\u5728\u62e5\u200b\u200b\u6709\u8db3\u591f\u7684\u6fb3\u5927\u5229\u4e9a\u8bd5\u9a8c\u573a\u5730\uff0c\u83b7\u5f97\u4e86\u79c1\u7acb\u548c\u516c\u7acb\u533b\u9662 HREC \u7684\u6279\u51c6\uff0c\u4ee5\u53ca\u6fb3\u5927\u5229\u4e9a\u6cbb\u7597\u7528\u54c1\u7ba1\u7406\u5c40\u7684\u6279\u51c6\u3002 \u5728\u6fb3\u5927\u5229\u4e9a\u9886\u5bfc\u8fd9\u9879\u8bd5\u9a8c\u7684\u662fSydney Eye\u533b\u9662\u3001Liverpool\u533b\u9662\u548cMacquarie \u533b\u9662\u7684\u795e\u7ecf\u773c\u79d1\u987e\u95ee Clare Fraser \u526f\u6559\u6388\u3002 Fraser\u535a\u58eb\u8bf4\uff0c\u8be5\u8bd5\u9a8c\u5c06\u63d0\u4f9b\u5fc5\u8981\u7684\u4e34\u5e8a\u8bc1\u636e\uff0c\u4ee5\u6f5c\u5728\u5730\u652f\u6301\u9488\u5bf9 IIH \u4e13\u5229\u7684\u65b0\u836f\u7269\u7597\u6cd5\uff0c\u5728\u73b0\u6709\u7597\u6cd5\u7f3a\u4e4f\u4e14\u4e34\u5e8a\u9700\u6c42\u5de8\u5927\u7684\u60c5\u51b5\u4e0b\u3002 Sinclair\u6559\u6388\u6307\u51fa\uff0cFraser\u535a\u58eb\u662f\u4e00\u4f4d\u201c\u56fd\u9645\u5730\u4f4d\u5f88\u9ad8\u201d\u7684\u795e\u7ecf\u773c\u79d1\u533b\u751f\u3002 \u9664\u4e86\u4e3aSydney Eye\u533b\u9662\u3001Liverpool\u533b\u9662\u548cMacquarie\u533b\u9662\u63d0\u4f9b\u54a8\u8be2\u5916\uff0cFraser\u535a\u58eb\u8fd8\u4e3a Save the Site Institute \u63d0\u4f9b\u54a8\u8be2\u670d\u52a1\uff0c\u62c5\u4efbNeuro-Ophthalmology Virtual Education Library\u526f\u4e3b\u5e2d\uff0c\u795e\u7ecf\u773c\u79d1\u5b66\u865a\u62df\u6559\u80b2\u56fe\u4e66\u9986\u59d4\u5458\u4f1a\u6210\u5458\uff0c\u5e76\u4e14\u662f\u51e0\u5bb6\u9ad8\u5f71\u54cd\u529b\u773c\u79d1\u671f\u520a\u7684\u7f16\u59d4\u3002 IIH EVOLVE&hellip; <a class=\"more-link\" href=\"https:\/\/smallcapscn.x5view.co\/?p=5864\">Continue reading <span class=\"screen-reader-text\">Invex Therapeutics \u5728\u83b7\u5f97\u7b2c\u4e8c\u6b21\u6fb3\u5927\u5229\u4e9a\u4f26\u7406\u6279\u51c6\u540e\u5f00\u8f9f\u4e86\u66f4\u591a\u8bd5\u9a8c\u573a\u6240<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":17781,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Invex Therapeutics \u5728\u83b7\u5f97\u7b2c\u4e8c\u6b21\u6fb3\u5927\u5229\u4e9a\u4f26\u7406\u6279\u51c6\u540e\u5f00\u8f9f\u4e86\u66f4\u591a\u8bd5\u9a8c\u573a\u6240<\/title>\n<meta name=\"description\" content=\"Invex Therapeutics (ASX: IXC) \u5df2\u5728\u6fb3\u5927\u5229\u4e9a\u83b7\u5f97\u7b2c\u4e8c\u4e2aHuman Research Ethics Committee (HREC) \u6279\u51c6\uff0c\u5f00\u59cb\u5176 III \u671f\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u4e3b\u8981\u836f\u7269 Presendin \u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics \u5728\u83b7\u5f97\u7b2c\u4e8c\u6b21\u6fb3\u5927\u5229\u4e9a\u4f26\u7406\u6279\u51c6\u540e\u5f00\u8f9f\u4e86\u66f4\u591a\u8bd5\u9a8c\u573a\u6240\" \/>\n<meta property=\"og:description\" content=\"Invex Therapeutics (ASX: IXC) \u5df2\u5728\u6fb3\u5927\u5229\u4e9a\u83b7\u5f97\u7b2c\u4e8c\u4e2aHuman Research Ethics Committee (HREC) \u6279\u51c6\uff0c\u5f00\u59cb\u5176 III \u671f\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u4e3b\u8981\u836f\u7269 Presendin \u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-30T01:13:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:55:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-Australian-approval-Alfred-Hospital-Melbourne-Liverpool-Sydney-Eye-Sydney.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/\",\"name\":\"Invex Therapeutics \u5728\u83b7\u5f97\u7b2c\u4e8c\u6b21\u6fb3\u5927\u5229\u4e9a\u4f26\u7406\u6279\u51c6\u540e\u5f00\u8f9f\u4e86\u66f4\u591a\u8bd5\u9a8c\u573a\u6240\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-09-30T01:13:10+00:00\",\"dateModified\":\"2023-08-29T17:55:44+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"Invex Therapeutics (ASX: IXC) \u5df2\u5728\u6fb3\u5927\u5229\u4e9a\u83b7\u5f97\u7b2c\u4e8c\u4e2aHuman Research Ethics Committee (HREC) \u6279\u51c6\uff0c\u5f00\u59cb\u5176 III \u671f\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u4e3b\u8981\u836f\u7269 Presendin \u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics \u5728\u83b7\u5f97\u7b2c\u4e8c\u6b21\u6fb3\u5927\u5229\u4e9a\u4f26\u7406\u6279\u51c6\u540e\u5f00\u8f9f\u4e86\u66f4\u591a\u8bd5\u9a8c\u573a\u6240\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics \u5728\u83b7\u5f97\u7b2c\u4e8c\u6b21\u6fb3\u5927\u5229\u4e9a\u4f26\u7406\u6279\u51c6\u540e\u5f00\u8f9f\u4e86\u66f4\u591a\u8bd5\u9a8c\u573a\u6240","description":"Invex Therapeutics (ASX: IXC) \u5df2\u5728\u6fb3\u5927\u5229\u4e9a\u83b7\u5f97\u7b2c\u4e8c\u4e2aHuman Research Ethics Committee (HREC) \u6279\u51c6\uff0c\u5f00\u59cb\u5176 III \u671f\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u4e3b\u8981\u836f\u7269 Presendin \u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics \u5728\u83b7\u5f97\u7b2c\u4e8c\u6b21\u6fb3\u5927\u5229\u4e9a\u4f26\u7406\u6279\u51c6\u540e\u5f00\u8f9f\u4e86\u66f4\u591a\u8bd5\u9a8c\u573a\u6240","og_description":"Invex Therapeutics (ASX: IXC) \u5df2\u5728\u6fb3\u5927\u5229\u4e9a\u83b7\u5f97\u7b2c\u4e8c\u4e2aHuman Research Ethics Committee (HREC) \u6279\u51c6\uff0c\u5f00\u59cb\u5176 III \u671f\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u4e3b\u8981\u836f\u7269 Presendin \u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/","og_site_name":"smallcapsCN","article_published_time":"2022-09-30T01:13:10+00:00","article_modified_time":"2023-08-29T17:55:44+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-Australian-approval-Alfred-Hospital-Melbourne-Liverpool-Sydney-Eye-Sydney.jpg","type":"image\/jpeg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/","name":"Invex Therapeutics \u5728\u83b7\u5f97\u7b2c\u4e8c\u6b21\u6fb3\u5927\u5229\u4e9a\u4f26\u7406\u6279\u51c6\u540e\u5f00\u8f9f\u4e86\u66f4\u591a\u8bd5\u9a8c\u573a\u6240","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-09-30T01:13:10+00:00","dateModified":"2023-08-29T17:55:44+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"Invex Therapeutics (ASX: IXC) \u5df2\u5728\u6fb3\u5927\u5229\u4e9a\u83b7\u5f97\u7b2c\u4e8c\u4e2aHuman Research Ethics Committee (HREC) \u6279\u51c6\uff0c\u5f00\u59cb\u5176 III \u671f\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u4e3b\u8981\u836f\u7269 Presendin \u5728\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-opens-up-more-trial-sites-second-australian-ethics-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics \u5728\u83b7\u5f97\u7b2c\u4e8c\u6b21\u6fb3\u5927\u5229\u4e9a\u4f26\u7406\u6279\u51c6\u540e\u5f00\u8f9f\u4e86\u66f4\u591a\u8bd5\u9a8c\u573a\u6240"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5864"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5864"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5864\/revisions"}],"predecessor-version":[{"id":15743,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5864\/revisions\/15743"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/17781"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}